Cite
Chang XL, Wu HL, Webb GM, et al. CCR5 Receptor Occupancy Analysis Reveals Increased Peripheral Blood CCR5+CD4+ T Cells Following Treatment With the Anti-CCR5 Antibody Leronlimab. Front Immunol. 2021;12:794638doi: 10.3389/fimmu.2021.794638.
Chang, X. L., Wu, H. L., Webb, G. M., Tiwary, M., Hughes, C., Reed, J. S., Hwang, J., Waytashek, C., Boyle, C., Pessoa, C., Sylwester, A. W., Morrow, D., Belica, K., Fischer, M., Kelly, S., Pourhassan, N., Bochart, R. M., Smedley, J., Recknor, C. P., Hansen, S. G., & Sacha, J. B. (2021). CCR5 Receptor Occupancy Analysis Reveals Increased Peripheral Blood CCR5+CD4+ T Cells Following Treatment With the Anti-CCR5 Antibody Leronlimab. Frontiers in immunology, 12794638. https://doi.org/10.3389/fimmu.2021.794638
Chang, Xiao L, et al. "CCR5 Receptor Occupancy Analysis Reveals Increased Peripheral Blood CCR5+CD4+ T Cells Following Treatment With the Anti-CCR5 Antibody Leronlimab." Frontiers in immunology vol. 12 (2021): 794638. doi: https://doi.org/10.3389/fimmu.2021.794638
Chang XL, Wu HL, Webb GM, Tiwary M, Hughes C, Reed JS, Hwang J, Waytashek C, Boyle C, Pessoa C, Sylwester AW, Morrow D, Belica K, Fischer M, Kelly S, Pourhassan N, Bochart RM, Smedley J, Recknor CP, Hansen SG, Sacha JB. CCR5 Receptor Occupancy Analysis Reveals Increased Peripheral Blood CCR5+CD4+ T Cells Following Treatment With the Anti-CCR5 Antibody Leronlimab. Front Immunol. 2021 Nov 19;12:794638. doi: 10.3389/fimmu.2021.794638. eCollection 2021. PMID: 34868084; PMCID: PMC8640501.
Copy
Download .nbib